'Pharmacy should base specials decisions on more than price' - An article Published by C&D

Please click here to view the article published 10th November 2011.

Comments

Post a Comment

Popular posts from this blog

Specials medicines vital for vulnerable patients

During the COVID-19 outbreak, APSM members are taking all appropriate measures to ensure the continuity of supply of specials medicines to community pharmacies, dispensing doctors and hospitals.   Specials manufacturers are a vital part of the pharmaceutical supply chain, responsible for around 50,000 unlicensed medicine prescriptions for vulnerable patients in England each month.  The Association of Pharmaceutical Specials Manufacturers represents around 80% of specials manufacture in England and its members are maintaining safe practices and committing to the ongoing fulfilment of all orders from their pharmacy customers throughout the pandemic. As specials are often prescribed to patients in vulnerable groups including the elderly, paediatrics and those with chronic health conditions, it has never been more important that these patients’ essential medication needs are met in a timely way.  Where possible, our members are continuing to meet thei...
Read more

Patient experience is at heart of decision to prescribe a special

When the Royal Pharmaceutical Society (RPS) updated it’s guidance on the procurement and supply of specials 1,  the focus was on putting the patient experience at the very heart of the process. The APSM supports this approach, believing that the emphasis on cost in recent years has sometimes clouded this underlying principle of a special provision. Says the RPS Guideline, the starting point is to establish the optimal treatment for the patient, this means that if a suitable licenced medicine is not available a Special must be offered to meet the patient’s special circumstances and urgency of need for treatment.  This basic decision to supply a Special therefore, cannot be based on cost or convenience.   Case Study: A GP prescribed an anti-inflammatory drug in a dispersible tablet formulation for a child with arthritis. A week later the mother returned to the GP because the child was still in pain despite giving the medicine as directed. The GP found o...
Read more

Specials record another year of delivering increased value to the NHS

The Specials Market in primary care was just over £ 80.5 million for the 12 month period Oct 15 - Sep 16.  Although the market continues to decline year-on-year, it is now stabilising following a period of readjustment in the wake of the Specials Tariff in November 2011.  During this time the mean cost per item has reduced from £180 per item before the tariff in Nov 2011, to an average £116 for the same 12 month period to Sep 2016. Whilst this represents value for money to the NHS, at the same time the high standards of quality involved in Specials manufacture have needed to be maintained.  According to the Association of Pharmaceutical Specials Manufacturers, APSM, members report continued investment in infrastructure and quality processes to meet the increasing regulatory demands required by the sector. To reflect the increased complexity of the market, l ast year (2016), the Association of Pharmaceutical Specials Manufacturers, APSM, decided to broaden its mem...
Read more